The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Open accessAbstract
Alzheimer’s disease, a major and increasing global health challenge, is an irreversible, progressive form of dementia, associated with an ongoing decline of brain functioning. The etiology of this disease is not completely understood, and no safe and effective anti-Alzheimer’s disease drug to prevent, stop, or reverse its evolution is currently available. Current pharmacotherapy concentrated on drugs that aimed to improve the cerebral acetylcholine levels by facilitating cholinergic neurotransmission through inhibiting cholinesterase. These compounds, recognized as cholinesterase inhibitors, offer a viable target across key sign domains of Alzheimer’s disease, but have a modest influence on improving the progression of this condition. In this paper, we sought to highlight the current understanding of the cholinergic system involvement in Alzheimer’s disease progression in relation to the recent status of the available cholinesterase inhibitors as effective therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“To date, the central neuropathological hallmarks noticed in AD are extracellular amyloid beta (Aβ) plaques, a consequence of aberrant transmembrane amyloid precursor protein (APP) cleavage, accumulation of large intracellular quantities of neurofibrillary tangles, cerebral amyloid angiopathy, glial cell dysfunction, s…”
BackgroundThe neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 3×
“Pharmacotherapeutic strategies for the AD treatment are mainly classified in the following ways: (i) Therapies that inhibit the onset of this condition by isolating the principal progenitors; (ii) disease‐modifying treatments termination or the reversal of disease progression; and (iii) symptomatic treatments that act…”
BackgroundBlood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 5×
“Subsequent findings of decreased choline uptake, ACh release and lack of cholinergic perikarya from the basal frontal lobe confirmed an important presynaptic cholinergic impairment [22].”
BackgroundInfluentialCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Alzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.
Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P. H., Silman, I., & Sussman, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.9031 · Cited by 899
Mitochondria and Mitochondrial Cascades in Alzheimer’s disease
Swerdlow, R. H. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170585 · Cited by 850
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · cited 1×
“Over time, a large number of strategies have been explored to overcome the BBB, instead quite limited by lack of specificity, safety issues and failure to reach adequate concentrations of released agents to appropriate volumes of brain tissue [82,83].”
BackgroundAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
Cholinesterase inhibitors as Alzheimer's therapeutics (Review)
Sharma, K. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10374 · Cited by 602
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506
Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine1
WANG, R., YAN, H., & TANG, X.-C. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00255.x · Cited by 470
Advances in the early detection of Alzheimer's disease
Nestor, P. J., Scheltens, P., & Hodges, J. R. (2004) · Nature Medicine · doi:10.1038/nrn1433 · Cited by 463
Acetylcholinesterase in Alzheimer's disease
Talesa, V. N. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00309-8 · Cited by 450
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Mehta, M., Adem, A., & Sabbagh, M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/728983 · Cited by 436
Molecular Pathogenesis of Alzheimer's Disease: An Update
Sanabria-Castro, A., Alvarado-Echeverría, I., & Monge-Bonilla, C. (2017) · Annals of Neurosciences · doi:10.1159/000464422 · Cited by 418
A Controlled Trial of Tacrine in Alzheimer's Disease
Farlow, M. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490180055026 · Cited by 398
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384
Nordberg, A., & Svensson, A.-L. (1998) · Drug Safety · doi:10.2165/00002018-199819060-00004 · Cited by 381
Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease
Giacobini, E. (2003) · Neurochemical Research · doi:10.1023/a:1022869222652 · Cited by 371
Role of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease
Ghosh, A. K., & Osswald, H. L. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60460h · Cited by 358
Alzheimer's Association Calcium Hypothesis Workgroup, & Khachaturian, Z. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.12.006 · Cited by 311
Buckingham, S. D., Jones, A. K., Brown, L. A., & Sattelle, D. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000562 · Cited by 308
The interplay of neurotransmitters in Alzheimer's disease
Francis, P. T. (2005) · CNS Spectrums · doi:10.1017/s1092852900014164 · Cited by 302 · cited 2×
“Molecular cloning has shown that a single gene encodes vertebrate acetylcholinesterase’s [19,21,22,31].”
BackgroundRole of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment
Lombardo, S., & Maskos, U. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.018 · Cited by 299
Tabet, N. (2006) · Age and Ageing · doi:10.1093/ageing/afl027 · Cited by 285 · cited 2×
“Homomeric forms are present in the cell as soluble species, probably intended for export or for association with the other cell membrane, usually by an attached glycophospholipide group [32].”
BackgroundAdvances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Blood–brain-barriers in aging and in Alzheimer’s disease
Marques, F., Sousa, J. C., Sousa, N., & Palha, J. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-38 · Cited by 274
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 268
Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., & Recanatini, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0340602 · Cited by 266
Multi-Target-Directed Ligands in Alzheimer's Disease Treatment
Bajda, M., Guzior, N., Ignasik, M., & Malawska, B. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797535245 · Cited by 240
A molecular approach in drug development for Alzheimer’s disease
Agatonovic-Kustrin, S., Kettle, C., & Morton, D. W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.147 · Cited by 233
Lu, C., Guo, Y., Yan, J., Luo, Z., Luo, H.-B., Yan, M., Huang, L., & Li, X. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400567s · Cited by 226
Muñoz-Ruiz, P., Rubio, L., García-Palomero, E., Dorronsoro, I., del Monte-Millán, M., Valenzuela, R., Usán, P., de Austria, C., Bartolini, M., Andrisano, V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503289 · Cited by 219
Yu, Q.-S., Holloway, H. W., Utsuki, T., Brossi, A., & Greig, N. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980459s · Cited by 210
Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects
Frozza, R. L., Lourenco, M. V., & De Felice, F. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00037 · Cited by 198
de Andrade Teles, R. B., Diniz, T. C., Costa Pinto, T. C., de Oliveira Júnior, R. G., Gama e Silva, M., de Lavor, É. M., Fernandes, A. W. C., de Oliveira, A. P., de Almeida Ribeiro, F. P. R., da Silva, A. A. M., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7043213 · Cited by 193
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis, F. (2002) · PubMed · Cited by 187
Singh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S., & Perry, G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7361613 · Cited by 186
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184 · cited 1×
“Administration of cholinesterase inhibitors such as donepezil is probably dependent on brain flow and a decrease in it will result in reduced absorption and thus reduced therapeutic effect [89].”
BackgroundThe histamine H3 receptor as a therapeutic drug target for CNS disorders
Gemkow, M. J., Davenport, A. J., Harich, S., Ellenbroek, B. A., Cesura, A., & Hallett, D. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.011 · Cited by 181
Amyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry
Mohamed, T., Shakeri, A., & Rao, P. P. N. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.049 · Cited by 180
Chen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00446 · Cited by 175
Camps, P., Formosa, X., Galdeano, C., Muñoz-Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badia, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 173
Metrifonate treatment of the cognitive deficits of Alzheimer's disease
Cummings, J. L., Cyrus, P. A., Bieber, F., Mas, J., Orazem, J., Gulanski, B., & The Metrifonate Study Group* (1998) · Neurology · doi:10.1212/wnl.50.5.1214 · Cited by 172
The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease
Rees, T. M., & Brimijoin, S. (2003) · Drugs of today · doi:10.1358/dot.2003.39.1.740206 · Cited by 171 · cited 2×
“During the enzymatic attack on acetylcholine, which is an ester with trigonal geometry, a tetrahedral intermediate is formed between the enzyme and the substrate [14,30].”
BackgroundDou, K.-X., Tan, M.-S., Tan, C.-C., Cao, X.-P., Hou, X.-H., Guo, Q.-H., Tan, L., Mok, V., & Yu, J.-T. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0457-9 · Cited by 171
M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Jiang, S., Li, Y., Zhang, C., Zhao, Y., Bu, G., Xu, H., & Zhang, Y. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1406-z · Cited by 170
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
Unzeta, M., Esteban, G., Bolea, I., Fogel, W. A., Ramsay, R. R., Youdim, M. B. H., Tipton, K. F., & Marco, J. L. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00205 · Cited by 170
Rivastigmine in the treatment of Alzheimer's disease: an update
Onor, M. L., Trevisiol, M., & Aguglia, E. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.17 · Cited by 161
Socio-economic Aspects of Alzheimer's Disease
Marešová, P., Mohelská, H., Dolejš, J., & Kuča, K. (2015) · Current Alzheimer Research · doi:10.2174/156720501209151019111448 · Cited by 156
Oshiro, S., Morioka, M. S., & Kikuchi, M. (2011) · Advances in Pharmacological Sciences · doi:10.1155/2011/378278 · Cited by 152
Wagstaff, A. J., & McTavish, D. (1994) · Drugs & Aging · doi:10.2165/00002512-199404060-00006 · Cited by 147
Geerts, H., Guillaumat, P.-O., Grantham, C., Bode, W., Anciaux, K., & Sachak, S. (2005) · Brain Research · doi:10.1016/j.brainres.2004.11.042 · Cited by 146
Histamine H3Receptor as a Drug Discovery Target
Berlin, M. Y., Boyce, C. W., & Ruiz, M. D. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100064d · Cited by 142
Prati, F., Bottegoni, G., Bolognesi, M. L., & Cavalli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00393 · Cited by 142
The role of nicotinic acetylcholine receptors in Alzheimer’s disease
Oddo, S., & LaFerla, F. M. (2006) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2005.12.080 · Cited by 132
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease
Martínez, A., & Castro, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.1.1 · Cited by 132
Smith, T. H., Sim‐Selley, L. J., & Selley, D. E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00777.x · Cited by 131
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease
Wu, Y., Li, Z., Huang, Y., Wu, D., & Luo, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01370 · Cited by 130
Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018)
Mishra, P., Kumar, A., & Panda, G. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.025 · Cited by 130
Novel insights for the treatment of Alzheimer's disease
Kurz, A., & Perneczky, R. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.018 · Cited by 129
Zhu, H., Yan, H., Tang, N., Li, X., Pang, P., Li, H., Chen, W., Guo, Y. A., Shu, S., Cai, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01943-0 · Cited by 126
The blood brain barrier in Alzheimer’s disease
Chakraborty, A., de Wit, N. M., van der Flier, W. M., & de Vries, H. E. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2016.11.008 · Cited by 118
Pi, R., Mao, X., Chao, X., Cheng, Z., Liu, M., Duan, X., Ye, M., Chen, X., Mei, Z., Liu, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031921 · Cited by 115
Targeting Alzheimer’s disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238
Rizzo, S., Bartolini, M., Ceccarini, L., Piazzi, L., Gobbi, S., Cavalli, A., Recanatini, M., Andrisano, V., & Rampa, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.071 · Cited by 108
Knez, D., Coquelle, N., Pišlar, A. H., Žakelj, S., Jukič, M., Sova, M., Mravljak, J., Nachon, F., Brazzolotto, X., Kos, J., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.033 · Cited by 98
Zueva, I. V., Dias, J., Lushchekina, S. V., Semenov, V. E., Mukhamedyarov, M. A., Pashirova, T. N., Babaev, V. M., Nachon, F., Petrova, N. V., Faritovich, N. L., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.025 · Cited by 98
Lemes, L. F. N., Ramos, G. D. A., de Oliveira, A. S., da Silva, F. M. R., Couto, G. C., Boni, M. S., Guimarães, M. J. R., Souza, I. N. D. O., Bartolini, M., Andrisano, V., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.024 · Cited by 94
Hollnagel, J., Elzoheiry, S., Gorgas, K., Kins, S., Beretta, C. A., Kirsch, J., Kuhse, J., Kann, O., & Kiss, É. (2019) · PLoS ONE · doi:10.1371/journal.pone.0209228 · Cited by 90
A Crosstalk Between Brain Cholesterol Oxidation and Glucose Metabolism in Alzheimer’s Disease
Gamba, P., Staurenghi, E., Testa, G., Giannelli, S., Sottero, B., & Leonarduzzi, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00556 · Cited by 90
Ghumatkar, P. J., Patil, S. P., Jain, P. D., Tambe, R., & Sathaye, S. S. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.06.005 · Cited by 87
Vohora, D., & Bhowmik, M. (2012) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2012.00072 · Cited by 85
Karthivashan, G., Park, S., Kweon, M., Kim, J.-S., Haque, M. E., Cho, D.-Y., Kim, I., Cho, E.-A., Ganesan, P., & Choi, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-25381-0 · Cited by 84
Lee, H., Fan, S.-J., Huang, F.-I., Chao, H.-Y., Hsu, K., Lin, T. E., Yeh, T., Lai, M.-J., Li, Y.-H., Huang, H.-L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00151 · Cited by 77
Sun, Y., Lai, M., Lu, C. ‐., & Chen, R. ‐. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.02049.x · Cited by 72
Kamal, M. A., Greig, N. H., Alhomida, A. S., & Al‐Jafari, A. A. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00330-0 · Cited by 70
Kumar, A., Tiwari, A. K., & Sharma, A. K. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180315141643 · Cited by 69
Predictions of Alzheimer’s disease treatment and care costs in European countries
Cimler, R., Marešová, P., Kühnová, J., & Kuča, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210958 · Cited by 68
Korábečný, J., Musílek, K., Holas, O., Binder, J., Zemek, F., Marek, J., Pohanka, M., Opletalová, V., Dohnal, V., & Kuča, K. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.044 · Cited by 67
Hall, H., Iulita, M. F., Gubert, P., Aguilar, L. F., Ducatenzeiler, A., Fisher, A., & Cuello, A. C. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.11.009 · Cited by 67
Girek, M. K., & Szymański, P. (2018) · Chemical Papers · doi:10.1007/s11696-018-0590-8 · Cited by 67
Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., & Melchiorre, C. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708785740652 · Cited by 66
Klein, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1087 · Cited by 66
Lange, J. H. M., Coolen, H. K. A. C., van der Neut, M. A. W., Borst, A. J. M., Stork, B., Verveer, P. C., & Kruse, C. G. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901614b · Cited by 64
A novel anti-Alzheimer's disease drug, ladostigil
Weinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00010-8 · Cited by 60
Lilja, A. M., Luo, Y., Yu, Q., Röjdner, J., Li, Y., Marini, A. M., Marutle, A., Nordberg, A. K., & Greig, N. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054887 · Cited by 59
Pavía, J., CEBALLOS, M. L. D., & de la Cuesta, F. S. (1998) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1998.tb00975.x · Cited by 52
New potential AChE inhibitor candidates
de Paula, A. A. N., Martins, J. B. L., dos Santos, M. L., Nascente, L. D. C., Romeiro, L. A. S., Areas, T. F. M. A., Vieira, K. S. T., Gambôa, N. F., Castro, N. G., & Gargano, R. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.03.045 · Cited by 52
Gustavsson, A., Green, C., Jones, R. W., Förstl, H., Simsek, D., de Vulpillieres, F. D. R., Luthman, S., Adlard, N., Bhattacharyya, S., & Wimo, A. B. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.005 · Cited by 50
Wang, Y., Guan, X., Chen, X., Cai, Y., Ma, Y., Ma, J., Zhang, Q., Dai, L., Fan, X., & Bai, Y. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201801407 · Cited by 49
De‐la‐Torre, P., Saavedra, L., Caballero, J., Jairo Quiroga, P., Alzate‐Morales, J. H., Cabrera, M., & Trilleras, J. E. (2012) · Molecules · doi:10.3390/molecules171012072 · Cited by 48
Oliveira, C., Cagide, F., Teixeira, J., Amorim, R., Sequeira, L., Mesiti, F., Silva, T., Garrido, J. M. P. J., Remião, F., Vilar, S., et al. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00126 · Cited by 45
Cashew Nut Shell Oil — A Renewable and Reliable Petrochemical Feedstock
Taiwo, E. A. (2015) · InTech eBooks · doi:10.5772/61096 · Cited by 43
Novel Benzothiazole-Based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer’s Disease Treatment
Aitken, L., Benek, O., McKelvie, B. E., Hughes, R. E., Hroch, L., Schmidt, M., Major, L. L., Vinklářová, L., Kuča, K., Smith, T., et al. (2019) · Molecules · doi:10.3390/molecules24152757 · Cited by 42
Zhen, J., Qian, Y., Fu, J., Su, R., An, H., Wang, W., Zheng, Y., & Wang, X. (2017) · Frontiers in Neural Circuits · doi:10.3389/fncir.2017.00048 · Cited by 41
Ko, Y., Kim, S. Y., Lee, S., & Jang, C. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.048 · Cited by 39
Mild cognitive impairment: animal models
Pepeu, G. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.4/gpepeu · Cited by 39
Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities
Zhan, Z., Bian, H.-L., Wang, J., & Shan, W. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.097 · Cited by 38
Zilony, N., Rosenberg, M., Richman, M., Yehuda, R., Schori, H., Motiei, M., Rahimipour, S., Groisman, A., Segal, E., & Shefi, O. (2019) · Small · doi:10.1002/smll.201904203 · Cited by 34
Benek, O., Hroch, L., Aitken, L., Gunn‐Moore, F. J., Vinklářová, L., Kuča, K., Pérez, D. I., Perez, C., Martı́nez, A., Fišar, Z., et al. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1445736 · Cited by 31
Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome
de Souza, F. M. S., Busquet, N., Blatner, M. J., Maclean, K. N., & Restrepo, D. (2011) · Scientific Reports · doi:10.1038/srep00137 · Cited by 30
McKeever, P. M., Kim, T. P., Hesketh, A. R., MacNair, L., Miletic, D., Favrin, G., Oliver, S. G., Zhang, Z., George‐Hyslop, P. S., & Robertson, J. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.014 · Cited by 29
Matsui, K., Taniguchi, S., & Yoshimura, T. (1999) · Xenobiotica · doi:10.1080/004982599237958 · Cited by 28
CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
Karami, A., Eriksdotter, M., Kadir, A., Almkvist, O., Nordberg, A. K., & Darreh‐Shori, T. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00239 · Cited by 26
Overview and perspective on the therapy of alzheimer's disease from a preclinical viewpoint
Pepeu, G. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00146-4 · Cited by 24
Endocannabinoid and Muscarinic Signaling Crosstalk in the 3xTg-AD Mouse Model of Alzheimer’s Disease
Llorente‐Ovejero, A., Manuel, I., Lombardero, L., Giralt, M. T., Ledent, C. A., Giménez‐Llort, L., & Rodríguez‐Puertas, R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180137 · Cited by 24
Xia, E., Xu, F., Hu, C., Kumal, J. P. P., Tang, X., Mao, D., Li, Y., Wu, D., Zhang, R., Wu, S., et al. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.08.010 · Cited by 22 · cited 1×
“In a similar manner, by administering venous blood from young mice to aged AD mice, it has been shown that this has neuroprotective effects and therapeutic effects over the hippocampal cholinergic input [104].”
BackgroundEffectiveness of rivastigmine in Alzheimer's disease
Bentham, P., Gray, R. G., Sellwood, E., Raftery, J., Rösler, M., Selai, C. E., Trimble, M., Rossor, M. N., Harvey, R. J., Storosum, J. G., et al. (1999) · BMJ · doi:10.1136/bmj.319.7210.640a · Cited by 21
Wang, D., Zhang, Q., Hu, X., Wang, W., Zhu, X., & Yuan, Z. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.10.039 · Cited by 21
Reale, M., D’Angelo, C., Costantini, E., Nicola, M. D., Yarla, N. S., Kamal, M. A., Salvador, N., & Perry, G. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170999 · Cited by 21
Amelioration of neurodegenerative diseases by cell death-induced cytoplasmic delivery of humanin
Park, T. Y., Kim, S., Shin, Y.-C., Lee, N.-H., Lee, R.-K. C., Shim, J., Glimcher, L. H., Mook‐Jung, I., Cheong, E., Kim, W.-K., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.022 · Cited by 20
Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD
Richter, N., Nellessen, N. D., Dronse, J., Dillen, K. N. H., Jacobs, H. I. L., Langen, K., Dietlein, M., Kracht, L., Neumaier, B., Fink, G. R., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101978 · Cited by 19
Metrifonate: A Cholinesterase Inhibitor for Alzheimer's Disease Therapy
Schneider, L. S. S., & Giacobini, E. (1999) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1999.tb00083.x · Cited by 14
Sato, T., Ohi, Y., Kato, D., Mizuno, M., Takase, H., Kanamori, T., Borlongan, C. V., Haji, A., & Matsukawa, N. (2017) · Cell Transplantation · doi:10.1177/0963689717721232 · Cited by 14
Nordberg, A. K., Kadir, A., Andreasen, N., Almkvist, O., Wall, A. E., Blennow, K., Långström, B., & Zetterberg, H. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-132474 · Cited by 11
Kim, M., Park, S., Lee, S., Kim, Y., Kim, Y. J., Jun, W., & Yoon, H. (2019) · Journal of Medicinal Food · doi:10.1089/jmf.2018.4375 · Cited by 9
Vila-Real, H. J., Coelho, H., Rocha, J. P., Fernandes, A. M. A., Ventura, M. R., Maycock, C. D., Iranzo, O., & Simplı́cio, A. L. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00658 · Cited by 7
Blood Brain Barrier Dysfunction and Cerebrovascular Degeneration in Alzheimer’s Disease
Kalaria, R. N. (2000) · Springer eBooks · doi:10.1007/978-94-017-1007-7_11 · Cited by 2
The role of butyrylcholinesterase in the pathogenesis of Alzheimer's disease
Wu, H., Li, X., Dantao, P., Jiao, J., Li, Y., Yu, P., & Ji, Y. S. (2017) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3969/cjcnn.v17i12.1711 · Cited by 1
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“481 When A β antibodies, such as bapineuzumab ( 31 ), did not yield signi fi cant therapeutic effects, research shifted towards inhibiting the formation of A β .”
BackgroundChen, Y., Xu, J., & Chen, Y. (2021) · Nutrients · doi:10.3390/nu13062099 · Cited by 917
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
Inflammatory pathways in Alzheimer’s disease mediated by gut microbiota
Qian, X.-H., Song, X.-X., Liu, X.-L., Chen, S.-D., & Tang, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101317 · Cited by 153
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Metadata
- Authors
- Stanciu, G. D., Luca, A., Rusu, R. N., Bild, V., Beschea Chiriac, S. I., Solcan, C., Bild, W., & Ababei, D. C.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2019-12-26
- Volume
- 10
- Issue
- 1
- Pages
- 40
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W2997708235
- Cited by
- 297
- References
- 133
- FWCI
- 13.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.